Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance

NCT03833440 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

114

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Durvalumab (MEDI4736)
DRUG: Monalizumab (IPH2201)
DRUG: Oleclumab (MEDI9447)
DRUG: Ceralasertib (AZD6738)
DRUG: DOCETAXEL
DRUG: Savolitinib

Sponsor

Assistance Publique Hopitaux De Marseille